Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Results of phase 3 of the CATIE schizophrenia trial.

Stroup TS, Lieberman JA, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK; CATIE Investigators.

Schizophr Res. 2009 Jan;107(1):1-12. doi: 10.1016/j.schres.2008.10.011. Epub 2008 Nov 21.

2.

Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.

McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):600-10.

PMID:
16585434
3.

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2006 Apr;163(4):611-22.

PMID:
16585435
4.

Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.

Stroup TS, Lieberman JA, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RS, Miller AL, Belz I, Hsiao JK; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):415-27.

PMID:
17329466
5.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
6.

Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.

Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, Lieberman JA; CATIE Investigators; Neurocognitive Working Group.

Arch Gen Psychiatry. 2007 Jun;64(6):633-47.

PMID:
17548746
7.

What CATIE found: results from the schizophrenia trial.

Swartz MS, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RS, Hsiao JK, Lieberman JA.

Psychiatr Serv. 2008 May;59(5):500-6. doi: 10.1176/appi.ps.59.5.500.

PMID:
18451005
8.

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators.

N Engl J Med. 2005 Sep 22;353(12):1209-23. Epub 2005 Sep 19. Erratum in: N Engl J Med. 2010 Sep 9;363(11):1092-3.

9.

Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.

Jing Y, Kim E, You M, Pikalov A, Tran QV.

J Med Econ. 2009 Jun;12(2):104-13. doi: 10.3111/13696990903044092.

PMID:
19527195
10.

Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.

Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RS, McEvoy JP, Hsiao JK, Lieberman JA; CATIE Investigators.

Am J Psychiatry. 2007 Mar;164(3):428-36.

PMID:
17329467
11.

Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia.

Olfson M, Gerhard T, Huang C, Lieberman JA, Bobo WV, Crystal S.

Schizophr Bull. 2012 Jun;38(4):845-53. doi: 10.1093/schbul/sbq172. Epub 2011 Feb 9.

12.

The impact of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) on prescribing practices: an analysis of data from a large midwestern state.

Berkowitz RL, Patel U, Ni Q, Parks JJ, Docherty JP.

J Clin Psychiatry. 2012 Apr;73(4):498-503. doi: 10.4088/JCP.10m06497. Epub 2011 Dec 13.

PMID:
22226332
13.

Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.

Van Dorn RA, Andel R, Boaz TL, Desmarais SL, Chandler K, Becker MA, Howe A.

J Clin Psychiatry. 2011 Apr;72(4):502-8. doi: 10.4088/JCP.10m06618.

PMID:
21527125
14.

Maintenance of response with atypical antipsychotics in the treatment of schizophrenia: a post-hoc analysis of 5 double-blind, randomized clinical trials.

Stauffer V, Ascher-Svanum H, Liu L, Ball T, Conley R.

BMC Psychiatry. 2009 Mar 31;9:13. doi: 10.1186/1471-244X-9-13.

15.

Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia.

Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD.

Schizophr Res. 2008 Jan;98(1-3):8-15. Epub 2007 Jun 26.

PMID:
17596914
16.

Choice of randomization to clozapine versus other second generation antipsychotics in the CATIE schizophrenia trial.

Hermes E, Rosenheck R.

J Psychopharmacol. 2012 Sep;26(9):1194-200. doi: 10.1177/0269881112443744. Epub 2012 Apr 19.

17.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416
18.

Ziprasidone versus olanzapine, risperidone or quetiapine in patients with chronic schizophrenia: a 12-week open-label, multicentre clinical trial.

Lublin H, Haug HJ, Koponen H, Sigmundsson T, Kolb SA.

World J Biol Psychiatry. 2009;10(4 Pt 3):710-8. doi: 10.1080/15622970802269589.

PMID:
18803070
19.

A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients Schizophrenia Trial of Aripiprazole: (STAR) study.

Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.

Eur Psychiatry. 2007 Oct;22(7):433-43. Epub 2007 Jun 7.

PMID:
17555947
20.

A model of anticholinergic activity of atypical antipsychotic medications.

Chew ML, Mulsant BH, Pollock BG, Lehman ME, Greenspan A, Kirshner MA, Bies RR, Kapur S, Gharabawi G.

Schizophr Res. 2006 Dec;88(1-3):63-72. Epub 2006 Aug 22.

PMID:
16928430
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk